Fulvestrant (ICI 182,780): High-Affinity Estrogen Receptor Antagonist for ER-Positive Breast Cancer Research

Executive Summary: Fulvestrant (ICI 182,780) is a selective estrogen receptor degrader (SERD) with an IC50 of 9.4 nM in ER-positive breast cancer models, resulting in potent ERα downregulation and signaling inhibition (APExBIO | Wang et al., 2021). It induces MDM2 protein reduction, cell cycle arrest, apoptosis, and enhances sensitivity to chemotherapeutic agents in MCF7 and T47D cell lines. Fulvestrant is soluble at ≥30.35 mg/mL in DMSO, used in vitro at 1–10 μM (up to 66 h), and inhibits tumor growth in ER+ xenograft models. APExBIO's Fulvestrant (A1428) is a validated resource for endocrine resistance and combination therapy research.

Biological Rationale

Estrogen receptor (ER) signaling is a central driver in the proliferation of ER-positive breast cancer cells. Approximately 70% of breast cancers express ERα, making anti-estrogen strategies clinically relevant (Wang et al., 2021). Fulvestrant (ICI 182,780) is a steroidal estrogen antagonist developed to overcome resistance to selective estrogen receptor modulators (SERMs) like tamoxifen. Unlike SERMs, Fulvestrant binds ERα with high affinity and promotes receptor degradation, leading to robust suppression of ER-mediated transcription and downstream proliferative signals (mechanistic review). This mechanism is crucial in models of endocrine resistance, where persistent ER signaling underpins tumor survival and progression.

Mechanism of Action of Fulvestrant (ICI 182,780)

Fulvestrant acts as a pure estrogen receptor antagonist by competitively binding ERα and inducing conformational changes that target the receptor for proteasomal degradation. This leads to a significant reduction in total cellular ER levels within hours of exposure. The compound disrupts the ER signaling pathway, downregulates ER target genes (e.g., PR, cyclin D1), and decreases the expression of oncogenic proteins such as MDM2. In vitro, Fulvestrant causes G1 cell cycle arrest, increases apoptosis, and triggers cellular senescence in ER-positive breast cancer cell lines (e.g., MCF7, T47D). In vivo, Fulvestrant inhibits tumor growth in estrogen-dependent xenograft models in nude mice.

Evidence & Benchmarks

• Fulvestrant exhibits an IC50 of 9.4 nM for ERα binding in competitive ligand-binding assays (APExBIO).
• ERα degradation and signaling inhibition observed within 6–24 h of 1–10 μM Fulvestrant treatment in MCF7 and T47D cells (Wang et al., 2021).
• Fulvestrant reduces MDM2 protein expression, increasing chemosensitivity to doxorubicin, paclitaxel, and etoposide in vitro (internal review).
• In vivo, Fulvestrant (ICI 182,780) induces significant tumor growth inhibition in ER+ human breast cancer xenograft models in nude mice (mechanistic evidence).
• Administration of ICI 182,780 abolishes the immunomodulatory effects of estrogen in rodent models, confirming its function as a robust ER antagonist (Wang et al., 2021).

Applications, Limits & Misconceptions

Fulvestrant (ICI 182,780) is widely used in research on ER-positive breast cancer, especially in the context of endocrine therapy resistance and chemotherapy sensitization. Its validated action in degrading ERα makes it a valuable tool for dissecting ER-dependent pathways, immune modulation, and cellular stress responses. The product is suitable for:

• In vitro studies of ER-mediated signaling and transcriptional regulation
• Mechanistic studies on cell cycle, apoptosis, and senescence in breast cancer cells
• Combination therapy experiments assessing chemosensitization
• In vivo efficacy in xenograft models (using clinically relevant dosing schedules)

This article extends prior overviews such as this mechanistic summary by providing granular, benchmarked application parameters. It also updates this internal review with recent evidence on immunomodulation and ER stress.

Common Pitfalls or Misconceptions

• Fulvestrant is not effective in ER-negative breast cancer models, as its mechanism depends on ERα binding and degradation.
• It is not water-soluble; incorrect solvent selection (water or PBS) will result in precipitation and loss of activity.
• Short-term exposure (<6 h) may be insufficient for complete ERα degradation; optimal in vitro exposure is 24–66 h.
• In vivo efficacy is species- and model-dependent; immune-competent models may yield variable results compared to nude mice.
• Fulvestrant is not interchangeable with SERMs (e.g., tamoxifen) due to its distinct SERD mechanism and lack of partial agonist activity.

Workflow Integration & Parameters

Fulvestrant (ICI 182,780) is supplied by APExBIO (SKU: A1428) as a solid, stable at -20°C, and soluble at ≥30.35 mg/mL in DMSO or ≥58.9 mg/mL in ethanol. For optimal solubility, warming to 37°C and ultrasonic shaking are recommended. Typical in vitro working concentrations are 1–10 μM, with incubation times up to 66 hours. In vivo, dosing regimens in nude mice mirror clinical intramuscular injection protocols (e.g., 250 mg/month, human equivalent). Stock solutions in DMSO remain stable for several months at -20°C. For additional workflow strategies and troubleshooting, see this application guide, which this article updates with newer stability and solubility data.

Researchers can source Fulvestrant (ICI 182,780) from APExBIO, ensuring batch-to-batch reproducibility and detailed product documentation. See also this modeling and troubleshooting guide for advanced use cases, which this article clarifies by specifying validated concentration and exposure benchmarks.

Conclusion & Outlook

Fulvestrant (ICI 182,780) is a gold-standard tool for ER-positive breast cancer research, enabling precise dissection of ER-mediated processes, resistance mechanisms, and chemotherapy response. Its high affinity, validated benchmarks, and reliable supply from APExBIO (A1428) make it indispensable in translational workflows. Ongoing research will further define its immunomodulatory effects and integration into combinatorial therapy regimens. For researchers requiring robust and reproducible ER antagonism, Fulvestrant (ICI 182,780) offers comprehensive validation and application guidance.